-
Company Insights
New![]()
Innovation and Patenting activity of GSK plc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of GSK plc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
New![]()
Net Present Value Model: GSK plc’s Men ABCWY
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: GSK plc’s AFX-3772
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: GSK plc’s Gepotidacin Mesylate
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: GSK plc’s Bepirovirsen Sodium
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
GlaxoSmithKline – GSK Tuas Vaccines Facility Expansion – South West
Equip yourself with the essential tools needed to make informed and profitable decisions with our GlaxoSmithKline – GSK Tuas Vaccines Facility Expansion – South West report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GSK-3923868 in Asthma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GSK-3923868 in Asthma Drug Details:GSK-3923868 is under development for the treatment of asthma and viral-induced COPD...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GSK-3772701 in Malaria
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GSK-3772701 in Malaria Drug Details:GSK-3772701 is under development for the treatment of malaria. The drug candidate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GSK-4406371A in Measles
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GSK-4406371A in Measles Drug Details:GSK-4406371A is under development for the prevention of measles, mumps, rubella, and varicella...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GSK-2256098 in Meningioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GSK-2256098 in MeningiomaDrug Details:GSK-2256098 is under development for the treatment of pancreatic ductal adenocarcinoma and progressive...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.